Haematological malignancy in pregnancy
|
|
- Verity Garrison
- 5 years ago
- Views:
Transcription
1 Haematological malignancy in pregnancy Dr Kylie Mason Haematologist Royal Melbourne Hospital / Peter MacCallum Cancer Centre NHMRC Fellow, University of Melbourne Senior Research Fellow, University of Sydney
2 Blood cancers are relatively rare
3 But are overrepresented in young people
4 Young people tend to more aggressive blood cancer Annual crude rates per : Haematological Malignancy Research Network (HMRN),
5 Haematologic malignancy in pregnancy is rare Incidence has been variably estimated from 1:1000 to 1:10,000 new cancer diagnoses in age by top 5 tumour type, Australia, 2014 Hodgkin Lymphoma % pregnancies Non Hodgkin Lymphoma: 0.016% Leukaemia 0.001% AIHW 2015
6 Lymphoma Non-Hodgkin Lymphoma 6th Most Common Cancer 4.1% of cancers in Australia 5500 new cases / year Incidence increases with age >60 subtypes can be roughly divided into indolent, intermediate and aggressive - which determine treatment strategy More aggressive lymphomas generally have higher cure rates treatment is with multi-agent chemotherapy +/- radiotherapy with variable outcomes Hodgkin Lymphoma Much less common 0.5% of cancers 400 new cases / year Dual peak incidence - Adolescence and young adults and >50yo good prognosis in most however outcomes for relapsed / refractory disease are very poor treatment is with multi-agent chemotherapy +/- radiotherapy with the goal of minimizing toxicity PET scans guide therapy with patients that are PET negative post 2 nd cycle of treatment having an excellent prognosis and ability to possibly reduce treatment
7 Leukaemia Myeloid vs Lymphoid Acute vs Chronic All present with signs and symptoms of bone marrow failure Can present with a hyper-leucostasis particularly AML Chronic Lymphocytic Leukaemia - disease of elderly, rare in younger women. Unlikely to need immediate treatment. Chronic Myeloid Leukaemia - now treated with tyrosine kinase inhibitors with excellent long term outcomes Acute Myeloid Leukaemia - most common acute leukaemia, can present with bleeding, gum infiltration, cutaneous disease Acute Lymphoblastic Leukaemia - can also present with mediastinal masses and lymphadenopathy
8 The path to cure is often more complex in pregnancy diagnosis staging treatment social support
9 Case 1 - diagnosis 32yo woman, G2P1, post partum depression with 1st child, history of anxiety shortness of breath, increased fatigue, loss of 3kg over pregnancy. investigated with increased fetal monitoring, regular ultrasounds confirmed normal fetal growth NVD at 39/40. no complications 3/52 post partum presented to A&E with stridor and hypoxia 1/52 night sweats cough since late pregnancy shortness of breath, fatigue and weight loss continued since birth
10 Case 1
11 Case 1 - PET
12 Classical Hodgkin Lymphoma Diagnosis
13 Diagnosis of haematological malignancy in pregnancy Many of the symptoms / signs of lymphoma and leukaemia are often seen in normal pregnancy, and dismissed as being normal for pregnancy fatigue shortness of breath itch anaemia, thrombocytopenia Occasionally increased monitoring during pregnancy can lead to incidental diagnosis - particularly with leukemia's that are diagnosed on a routine FBE.
14 Pregnancy should never preclude an adequate diagnostic biopsy critical to obtain a tissue diagnosis allows treatment stratification and prognostication critical in pregnancy as it may be that treatment can be delayed / minimised until post delivery Lymphoma: adequate biopsy (a core or excisional biopsy, never a FNA) Leukaemia: Bone Marrow Aspirate and Trephine An adequate first biopsy is essential to avoid delay and further complications. Always consult a haematologist early if there is a suspicion of a haematological malignancy
15 Case 2 - staging 27yo G1P0 18/40 presents with rapidly enlarging cervical lymph node no prior medical history, uncomplicated pregnancy to date clinical examination: well looking, no other palpable lymphadenopathy or hepatosplenomegaly. good air entry bilaterally CXR: normal Biopsy - Classical Hodgkin Lymphoma Preferred staging is PET / CT scan - alternatives in pregnancy?
16 Choice of imaging depends on gestation American College of Obstetricians and Gynecologists committee - I maging in pregnancy
17 Staging should be completed if possible Lymphoma FBE, UEC, LDH, HepB,C, HIV, SPEP, Ca/Mg/Po4 Imaging tests (X-ray, CT, MRI, PET scan) Bone marrow biopsy Lumbar puncture (in aggressive disease) 24-hour urine collection whilst purpose of staging is to establish extent of disease, investigations to establish safety / baseline for treatment are also does - e.g.: RFT s, cardiac assessment with GBPS or echo, viral serology Leukaemia lymphoid leukaemia, particularly T-ALL, require imaging of mediastinum cytogenetic and molecular markers - greatest prognostic tool lumbar puncture blood tests
18 Staging in pregnancy avoidance of fetal irradiation if possible MRI is scan of choice PET scan is relatively safe in pregnancy: fetal radiation dose is below 2.4mGy (below threshold dose for deterministic fetal events) recommend give vigorous hydration and diuresis to minimise fetal exposure to irradiation
19 MRI for lymphoma staging
20 Case 3 - early pregnancy 24yo woman undergoing treatment of primary CNS lymphoma completed 6 cycles of high dose methotrexate chemotherapy and commenced high dose cranial irradiation presents for routine MRI scan and announces that she is approximately 8 weeks pregnant. conception likely to have occurred prior to admission for high dose methotrexate. High Dose methotrexate and Cranial Irradiation given whilst (unknowingly) pregnant.
21 Chemotherapy in first trimester Chemotherapy during the first trimester is associated with the risk of spontaneous abortions, fetal death and major malformations Overall the rate of major malformations is 10 20%. If a diagnosis of malignancy is made in first trimester - termination of pregnancy should be considered and treatment proceeds as per standard protocol. options for non-chemotherapy base treatment should be considered and discussed, however best practice maternal treatment should be the goal The risk of fetal complications increases with combination chemotherapy vs single agent chemotherapy, and is less if anti-metabolites are excluded.
22 Case 4 - treatment 32yo married mother of 2 working part time G3P2, 2 prior NVD s with uncomplicated pregnancies 24 weeks: routine FBE at obstetric review: Hb 85g/dL total WCC 1.3x19^9/L Platelets 21 x 10^9/L Film: immature blasts on film Diagnosis:Acute Lymphoblastic Leukaemia
23 2nd and 3rd Trimesters: Principles of treatment The priority is appropriate delivery of life-saving maternal treatment with harm minimization to fetus Survival rates of haematologic malignancy in pregnancy are the same as age / stage matched non-pregnant controls Greatest risk to fetal health is premature delivery - aim for delivery as close to term as practical Outcome of children exposed in utero (2 nd and 3 rd trimesters) to chemotherapy is the same as peers for intellectual physical, neurological and social development, as are grandchildren of mothers exposed to chemotherapy during pregnancy.
24 Hodgkin Lymphoma Early stage disease Advanced disease Novel agents standard treatment ABVD combination therapy BEACOPP, MOPP or Stanford V combination therapies Brentuximab modification in pregnancy good evidence that standard treatment is well tolerated with no adverse outcome to foetus or mother no evidence. Aim to give ABVD and intensify treatment post delivery No evidence. monoclonal antibody to CD30
25 Non-Hodgkin Lymphoma Standard treatment Modification in pregnancy Indolent disease (ie: Follicular Lymphoma) watch and wait or Bendamustine / Rituximab chemotherapy watch and wait advised with careful monitoring. treat post-partum Intermediate (ie Diffuse Large B cell Lymphoma) R-CHOP (rituximab - monoclonal anti-cd20, plus anthracycline base combination chemotherapy) R-CHOP is well tolerated with good maternal and fetal outcomes Aggressive (ie: Burkitt Lyphoma, Mantle cell lymphoma) high dose, highly intensive multiagent regimes i.e.: CODOX-M/IVAC high maternal mortality if not treated promptly. termination of pregnancy highly recommended high dose methotrexate is important part of treatment - severe fetal myelosuppression Can treat with IVAC then deliver if delivery not viable at diagnosis / termination not desirable Specific Ie Primary CNS Lymphoma, T cell lymphomas, Treatments are increasingly specific not only to disease subtype but molecular stratification Individualize therapy with principles of trying to achieve as close to standard treatment of malignancy with minimal fetal harm
26 Acute Lymphoblastic leukaemia standard treatment is stratified by age, and risk factors <30 yo - paediatric protocol with high intensity multiagent chemotherapy based on a backbone of vinca alkaloids, methotrexate, anthracyclines Well tolerated in pregnancy with the exception of methotrexate and L Aspinaginase >30yo - standard is HyperCVAD - poorly tolerated in pregnancy - use paediatric protocol until post delivery then individualize approach to catch up on doses required.
27 Acute Myeloid Leukaemia Fetal loss is highly likely in first trimester and spontaneous abortion is risky. Elective termination should be considered Greater than 32 weeks gestation, early delivery should be considered Early initiation of treatment should be a priority Standard treatment is with high dose anthracycline and Cytarabine (7&3) and whilst associated with risks of fetal exposure to chemotherapy are best option to reduce risks of early delivery and prematurity Plan delivery at 3 weeks post chemotherapy to minimize chance of cytopenias and sequale such as infection and bleeding Exception is Acute pro-myelocytic leukaemia - excellent prognosis with ATRA (vit A derivative). Responses with single agent ATRA therapy should be closely monitored (molecular testing) and give chemotherapy only when complications arise or post delivery).
28 Supportive care in the pregnant patient delivery of chemotherapy successfully requires multiple prophylactic and supportive medications in pregnancy - risk is high to both mother and baby with a septic episode literature from HIV population studies are most helpful anti-fungal - Voriconazole is preferred anti-fungal prophylaxis, however relatively contraindicated in pregnancy non-liposomal amphotericin has safest profile in pregnancy, with Ambisome being used in case studies with no adverse effect. Currently recommended anti-fungal in pregnancy Ambisome can cross the placenta and can contribute to fetal renal dysfunction. Azoles and caspofungin are teratogenic up to 23 weeks. anti-viral - Valaciclovir - safe in pregnancy anti-pcp - Bactrim DS - considered relatively safe anti-emetics - well documented in pregnancy tumour lysis prophylaxis - Allopurinol - avoid in fist trimester, otherwise proceed with caution. GIT protection - Rantidine is standard and is well tolerated in pregnancy
29 Timing of delivery Where possible delivery should be planned to avoid higher risks associated with complications of chemotherapy Caesarian section should only be recommended for obstetric indications common side effects of chemotherapy peak at 7-10 days post commencement of chemotherapy thrombocytopenia - often profound nadir depends on chemotherapy protocol, but generally is around 10 days with recovery by day 20 neutropenia - often absolute with nadir around 7-10 days with faster recovery than platelets. GIT - nausea, vomiting, ileus, enterocolitis, timing parallels neutropenia critical to have a multidisciplinary team and close liaison between obstetric and haematology teams, to monitor pregnancy and time delivery Avoid epidural when platelets <80 x 10^9/L or neutrophils <1 x 10^9/L Post-partum - potential high risk of thrombosis - discuss anticoagulation aim for recommencement of chemotherapy as soon as is practical, depending on stage of disease, chemotherapy already given and complications of delivery
30 Breast feeding Whilst breast feeding is often desired by the mother and medial team, it is often not practical mother and child are often separated for long periods of time physical, social and practical issues In general avoid breast feeding for a period of two weeks following chemotherapy administration If the anti-cancer treatment is acceptable in breast milk - often the supportive / prophylactic medications are not. Breastfeeding should be avoided for 24 hours after a PET scan. (restaging is often done post - partum to re-assess and plan for ongoing treatment) Important to engage team from obstetrics for management of weaning and reduce the risk of mastitis Specific drugs: ATRA & Arsenic avoid cardiac toxicity in infant IFN-a excreted in breast milk, avoid breast feeding TKI s excreted in breast milk, recommend to avoid breast feeding however some case reports with good outcomes Many of the novel agents there is little to no information available
31 Impact of cancer in pregnancy is long-lasting Impact of cancer diagnosis on young family restructure of family roles (especially with regards to primary childcare roles) poor bonding with baby, often unable to room in once moved to nonmaternity hospital delivery often stressful, culmination of weeks / months planning, but also signals start of more intensive treatment treatment may be ongoing for months or years, or include other modalities such as bone marrow transplantation Financial issues - sick leave may not available as maternity leave planned Income replacing insurance may be denied as planned maternity leave
32 Cancer in pregnancy be aware of the presentations of leukaemia and lymphoma in pregnancy transfer to a high risk obstetric unit with close links to a haematology unit experienced in obstetric medicine close liaison with obstetricians, midwives and haematologists, with a strong back up with social work obstetric support needs to continue post partum - management of lactation, regular mother - baby follow up support for the whole family with recognition of secondary carers
33 The outcomes Case 1-post partum dx of Hodgkin lymphoma Initially achieved good response with chemotherapy Never achieved CR Despite allograft and novel therapy disease progressed. Died 2 years post diagnosis. Case 2 - Hodgkin lymphoma at 24 weeks managed with a combination of dexamethasone and cyclophosphamide until delivery at 34 weeks completed 6 cycles of ABVD chemotherapy post partum remains in CR1 7 years later and has had another child naturally Case 3 - conception post high dose methotrexate / radiotherapy elected to proceed with pregnancy monitored closely for fetal malformations and relapse of CNS lymphoma delivered healthy boy at term presented for next MRI - 4 months post partum - was pregnant again!! Case 4 - ALL at 24 weeks treated with paediatric protocol and at time of delivery was in morphologic CR. went on to have 6 months of intensive chemotherapy but never achieved a molecular remission. bone marrow transplant from unrelated donor relapsed 3 months post transplant Remains in CR 3 years later. Eldest child being investigated for developmental delay received immunomodulatory therapy and remains in remission 5 years post transplant 6 years post diagnosis has returned to work, and formed a strong bond with her son who started school this year
What is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias
Hematology and Hematologic Malignancies Cancer of the formed elements of the blood What is a hematological malignancy? A hematologic malignancy is a malignancy (or cancer) of any of the formed elements
More informationLEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University
LEUKAEMIA and LYMPHOMA Dr Mubarak Abdelrahman Assistant Professor Jazan University OBJECTIVES Identify etiology and epidemiology for leukemia and lymphoma. Discuss common types of leukemia. Distinguish
More informationWHAT ARE PAEDIATRIC CANCERS
WHAT ARE PAEDIATRIC CANCERS INTRODUCTION Childhood cancers are RARE 0.5% of all cancers in the West Overall risk that a child will develop cancer during first 15 years of life is 1 in 450 and 1 in 600
More informationLYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center
LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center Lymphoma is cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make up and store cells
More informationThis is a controlled document and therefore must not be changed or photocopied L.80 - R-CHOP-21 / CHOP-21
R- / INDICATION Lymphoma Histiocytosis Omit rituximab if CD20-negative. TREATMENT INTENT Disease modification or curative depending on clinical circumstances PRE-ASSESSMENT 1. Ensure histology is confirmed
More informationLymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC
Lymphoma: What You Need to Know Richard van der Jagt MD, FRCPC Overview Concepts, classification, biology Epidemiology Clinical presentation Diagnosis Staging Three important types of lymphoma Conceptualizing
More informationHAEMATOLOGICAL MALIGNANCY
HAEMATOLOGICAL MALIGNANCY Reference Compulsory reading Haematology at Glance 2 nd ed. Atul Mehta & Victor Hoffbrand Chapters: 20 to 31 Pages: 46 to 69 Pathogenesis of Haematological Malignancy Figure (a)
More informationUnderstanding your diagnosis. Dr Graham Collins Consultant Haemtologist Oxford University Hospitals
Understanding your diagnosis Dr Graham Collins Consultant Haemtologist Oxford University Hospitals Common questions I get asked What is lymphoma? What subtype do I have and what does that mean? What are
More informationBlood Cancers in the Community
Over to you, mate Blood Cancers in the Community National Rural Health Conference NZ Rural General Practice Network April 7, 2018 Brian Grainger Haematology Registrar Auckland Acknowledgements Dr James
More informationElements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Chronic lymphocytic leukaemia 1 Chronic lymphocytic leukemia (CLL) is a condition characterized by a progressive accumulation
More informationSUMMARY OF THE RISK MANAGEMENT PLAN FOR. BESPONSA 1mg (INOTUZUMAB OZOGAMICIN) Powder for concentrate for solution for infusion.
SUMMARY OF THE RISK MANAGEMENT PLAN FOR BESPONSA 1mg (INOTUZUMAB OZOGAMICIN) Powder for concentrate for solution for infusion. This RMP Summary is based on Part VI of the EU RMP for BESPONSA (Inotuzumab
More informationBlood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen
Blood Cancers: Progress and Promise Mike Barnett & Khaled Ramadan Division of Hematology Department of Medicine Providence Health Care & UBC Blood Cancers Significant health problem Arise from normal cells
More informationLarge cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s
Non Hodgkin s Lymphoma Introduction 6th most common cause of cancer death in United States. Increasing in incidence and mortality. Since 1970, the incidence of has almost doubled. Overview The types of
More informationNote: There are other bendamustine protocols, ensure this is the correct one for a given patient.
INDICATIONS 1 st line treatment for follicular lymphoma with FLIPI score 2 or higher: (NICE TA513- BLUETEQ required) Rituximab refractory follicular lymphoma (progression on R-chemo, R-maintenance or within
More informationAggressive Lymphomas - Current. Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre
Aggressive Lymphomas - Current Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre Conflicts of interest I have no conflicts of interest to declare Outline What does aggressive lymphoma
More informationAppendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand
Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand This list provides indications for the majority of adult BMTs that are performed in New Zealand. A small number of BMTs
More informationHaematological malignancies in England Cancers Diagnosed Haematological malignancies in England Cancers Diagnosed
Northern and Yorkshire Cancer Registry and Information Service Haematological malignancies in England Cancers Diagnosed 2001-2008 Haematological 2001-2008 Malignancies www.nycris.nhs.uk www.nycris.nhs.uk
More informationTiming and complications of allogeneic stem cell transplant in Ph + ALL
Timing and complications of allogeneic stem cell transplant in Ph + ALL Dr Ashlea Campbell Haematology Advanced Trainee Concord Repatriation and General Hospital Royal Prince Alfred Hospital 24 th Feb
More informationNon-Hodgkin lymphoma
Non-Hodgkin lymphoma Non-Hodgkin s lymphoma Definition: - clonal tumours of mature and immature B cells, T cells or NK cells - highly heterogeneous, both histologically and clinically Non-Hodgkin lymphoma
More informationSummary of the risk management plan (RMP) for Gazyvaro (obinutuzumab)
EMA/319729/2014 Summary of the risk management plan (RMP) for Gazyvaro (obinutuzumab) This is a summary of the risk management plan (RMP) for Gazyvaro, which details the measures to be taken in order to
More informationIndolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital
Indolent Lymphomas Dr. Melissa Toupin The Ottawa Hospital What does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with
More informationCandidates must answer ALL questions
Time allowed: Three hours. Part 1 examination Haematology: First paper Tuesday 22 March 2016 Candidates must answer ALL questions Question 1: General Haematology A 16 year old non-european is referred
More informationLancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:
1 Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma: 2018-19 1.1 Pretreatment evaluation The following tests should be performed: FBC, U&Es, creat, LFTs, calcium, LDH, Igs/serum
More informationSkin Pathway Group Alemtuzumab in Cutaneous Lymphoma
Skin Pathway Group Alemtuzumab in Cutaneous Lymphoma Indication: Treatment of patients with Cutaneous Lymphoma (Unlicensed use) Disease control prior to Reduced Intensity Conditioning Stem Cell Transplant
More informationLymphoma is a cancer that develops in the white blood cells (lymphocytes) of the lymphatic system, which is part of the body's immune system.
Scan for mobile link. Lymphoma Lymphoma is a cancer that develops in the white blood cells of the lymphatic system. Symptoms may include enlarged lymph nodes, unexplained weight loss, fatigue, night sweats
More informationNon-Hodgkin Lymphoma in Clinically Difficult Situations
Winship Cancer Institute of Emory University Non-Hodgkin Lymphoma in Clinically Difficult Situations James Armitage, MD Professor, Department of Internal Medicine Joe Shapiro Distinguished Chair of Oncology
More informationNorth West London Cancer Network
GUIDELINES FOR THE MANAGEMENT OF ADULT ACUTE LEUKAEMIA INITIAL MANAGEMENT CONSIDERATIONS N.B.: If AML is suspected definitively diagnosed, please ensure that the patient is transferred immediately f treatment
More informationPediatric Oncology. Vlad Radulescu, MD
Pediatric Oncology Vlad Radulescu, MD Objectives Review the epidemiology of childhood cancer Discuss the presenting signs and symptoms, general treatment principles and overall prognosis of the most common
More informationIf unqualified, Complete remission is considered to be Haematological complete remission
Scroll right to see the database codes for Disease status and Response Diagnosis it refers to Disease status or response to treatment AML ALL CML CLL MDS or MD/MPN or acute leukaemia secondary to previous
More informationLymphoma John P. Leonard, M.D.
Lymphoma 2017 John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department of Medicine Disclosures Consulting
More informationIf unqualified, Complete remission is considered to be Haematological complete remission
Scroll right to see the database codes for Disease status and Response Diagnosis it refers to Disease status or response to treatment AML ALL CML CLL MDS or MD/MPN or acute leukaemia secondary to previous
More informationIndolent Lymphomas: Current. Dr. Laurie Sehn
Indolent Lymphomas: Current Dr. Laurie Sehn Why does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with current standard
More information1. Please review the following table, make any changes you think are necessary and highlight those changes. Feel free to put notes on the next page
COME HOME Non-Hodgkin pathway development worksheet, v6 September 2014 1. Please review the following table, make any changes you think are necessary and highlight those changes. Feel free to put notes
More informationSOUTH THAMES CHILDREN S CANCER NETWORK GROUP. REFERRAL PROTOCOLS AND DIAGNOSIS AND STAGING PROTOCOLS October 2014
SOUTH THAMES CHILDREN S CANCER NETWORK GROUP REFERRAL PROTOCOLS AND DIAGNOSIS AND STAGING PROTOCOLS October 2014 Contents 1. Leukaemia Referral, Diagnostic and Staging Guidelines 2. Lymphoma Referral,
More informationLeukemias. Prof. Mutti Ullah Khan Head of Department Medical Unit-II Holy Family Hospital Rawalpindi Medical College
Leukemias Prof. Mutti Ullah Khan Head of Department Medical Unit-II Holy Family Hospital Rawalpindi Medical College Introduction Leukaemias are malignant disorders of the haematopoietic stem cell compartment,
More information1.28 Protocol Name: CODOX-M/IVAC
1.28 Protocol Name: CODOX-M/IVAC Indication Burkitt's or Burkitt's-like lymphoma - especially those with 1 of the following poor risk criteria: Lymphoblastic lymphoma - especially B subtype Acute Myeloid
More informationNON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More informationInstructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113)
Instructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the CLL Post-HSCT Data Form. E-mail
More informationX M/ (R) Dose adjusted (DA)-EPOCH-R
X M/ (R) adjusted (DA)-EPOCH-R Indication High-risk CD20+ diffuse large B cell lymphoma especially C-MYC and BCL-2 activated (i.e. double hit lymphoma) and mediastinal sclerosing (thymic) large B cell
More informationCHEMOTHERAPY PROTOCOL FOR ADMINISTRATION OF VENETOCLAX
CHEMOTHERAPY PROTOCOL FOR ADMINISTRATION OF VENETOCLAX Therapeutic Indications: Venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion
More informationHigh Intensity Chemotherapy Guidelines for Haematology Patients at ASPH
High Intensity Chemotherapy Guidelines for Haematology Patients at ASPH Contents: Page No. 1. Overview 2 2. Admission 3 3. Admission Checklist 5 4. Inpatient management during chemotherapy 6 5. Inpatient
More informationLymphoma 101. Nathalie Johnson, MDPhD. Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University
Lymphoma 101 Nathalie Johnson, MDPhD Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University Disclosures Consultant and Advisory boards for multiple companies
More informationDiagnosis and patient pathway in lymphomas
The Royal Marsden Diagnosis and patient pathway in lymphomas Dr Ian Chau Consultant Medical Oncologist The Royal Marsden Hospital London & Surrey Change Presentation title and date in Footer dd.mm.yyyy
More information(R) CHOEP. May be used for stage IA - IV Diffuse Large B Cell non-hodgkin lymphoma in combination with rituximab.
(R) CHOEP Indication Treatment of stage IA - IV T cell non-hodgkin lymphoma as an alternative to CHOP in younger, fitter patients with normal LDH level. May be used for stage IA - IV Diffuse Large B Cell
More informationMantle Cell Lymphoma
Mantle Cell Lymphoma Clinical Case A 56 year-old woman complains of pain and fullness in the left superior abdominal quadrant for the last 8 months. She has lost 25 kg, and lately has had night sweats.
More informationVI.2 Elements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Leukaemia is a cancer that starts in the blood-forming cells of the bone marrow. Chronic lymphocytic leukaemia (CLL) is a type
More informationHodgkin's Lymphoma. Symptoms. Types
Hodgkin's lymphoma (Hodgkin's disease) usually develops in the lymphatic system, a part of the body's immune system. This system carries disease-fighting white blood cells throughout the body. Lymph tissue
More informationLymphoma: The Basics. Dr. Douglas Stewart
Lymphoma: The Basics Dr. Douglas Stewart Objectives What is lymphoma? How common is it? Why does it occur? How do you diagnose it? How do you manage it? How do you follow patients after treatment? What
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More information2.07 Protocol Name: CHOP & Rituximab
2.07 Protocol Name: CHOP & Rituximab Indication Intermediate and high grade, B-cell non-hodgkins lymphoma expressing CD20. Second or third line therapy for low grade, B cell non- Hodgkins lymphoma expressing
More informationAcute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010
Acute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010 ALL Epidemiology 20% of new acute leukemia cases in adults 5200 new cases in 2007 Most are de novo Therapy-related
More informationNON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and
More informationGuidelines for the Management of Chronic Lymphocytic Leukaemia (CLL)
Guidelines for the Management of Chronic Lymphocytic Leukaemia (CLL) Version History Version Date Summary of Change/Process 2.0 08.05.08 Endorsed by the Governance Committee 2.1 16.02.11 Circulated at
More informationLymphatic system component
Introduction Lymphatic system component Statistics Overview Lymphoma Non Hodgkin s Lymphoma Non- Hodgkin's is a type of cancer that originates in the lymphatic system. It is estimated to be the sixth most
More informationBurkitt s Lymphoma or DLBCL with adverse features PATIENTS WITH GOOD PERFORMANCE STATUS
Regimen R-CODOX M Indication Burkitt s Lymphoma or DLBCL with adverse features Therapeutic Intent Radical/Curative PATIENTS WITH GOOD PERFORMANCE STATUS Day Medication Dose Route Administration Details
More informationNational Cancer Intelligence Network Trends in incidence and outcome for haematological cancers in England:
National Cancer Intelligence Network Trends in incidence and outcome for haematological cancers in England: 2001-2010 Trends in incidence and outcome for haematological cancers in England: 2001-2010 About
More informationPart 1 examination. Haematology: First paper. Tuesday 20 March Candidates must answer all questions. Each question is worth a total of 25 marks.
Part 1 examination Haematology: First paper Tuesday 20 March 2018 Candidates must answer all questions. Each question is worth a total of 25 marks. Time allowed: 3 hours Question 1: General Haematology
More informationThis is a controlled document and therefore must not be changed
AZACITIDINE NICE TA218 Treatment of adults not eligible for haematopoietic stem cell transplantation who have: Intermediate-2 and high-risk MDS according to the International Prognostic Scoring System
More informationNon-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)
Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL) Lymphoid Neoplasms: 1- non-hodgkin lymphomas (NHLs) 2- Hodgkin lymphoma 3- plasma cell neoplasms Non-Hodgkin lymphomas (NHLs) Acute Lymphoblastic Leukemia/Lymphoma
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationAllogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Policy Specific Section:
Medical Policy Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Type: Medical Necessity and Investigational / Experimental Policy Specific Section:
More informationLeukocytosis - Some Learning Points
Leukocytosis - Some Learning Points Koh Liang Piu Department of Hematology-Oncology National University Cancer Institute National University Health System Objectives of this talk: 1. To provide some useful
More informationR-GemOx. Lymphoma group INDICATION. Relapsed or Refractory Lymphoma, for patients unsuitable for R-GDP regimen. Omit rituximab if CD20- negative
R-GemOx INDICATION Relapsed or Refractory Lymphoma, for patients unsuitable for R-GDP regimen. Omit rituximab if CD20- negative TREATMENT INTENT Disease modification PRE-ASSESSMENT 1. Ensure histology
More informationPathology of Hematopoietic and Lymphoid tissue
CONTENTS Pathology of Hematopoietic and Lymphoid tissue White blood cells and lymph nodes Quantitative disorder of white blood cells Reactive lymphadenopathies Infectious lymphadenitis Tumor metastasis
More informationCD20-positive high-grade non-hodgkin Lymphoma in patients in which R-CHOP is not indicated
INDICATION CD20-positive high-grade non-hodgkin Lymphoma in patients in which R-CHOP is not indicated TREATMENT INTENT Curative or Disease Modification. PRE-ASSESSMENT 1. Ensure histology is confirmed
More informationPolicy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies
Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies UNCONTROLLED WHEN PRINTED Note: NOSCAN Haematology MCN has approved the information contained within this document to guide
More informationLymphomas and multiple myeloma 12/23/2018 1
60 Lymphomas and multiple myeloma 12/23/2018 1 Lymphomas Lymphoma is cancer of the lymphatic system. Lymphomas are subdivided into two main categories: Hodgkin's lymphoma (HL) and non- Hodgkin's lymphoma
More informationAnimal chemotherapy Film radiotherapy Music cancer treatment
Cancer treatments Animal chemotherapy Film radiotherapy Music cancer treatment What are the main treatments? Hormone therapy Surgery Chemotherapy Radiotherapy Targeted anti-cancer therapy (immunotherapy)
More informationCLL: disease specific biology and current treatment. Dr. Nathalie Johnson
CLL: disease specific biology and current treatment Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck
More information2012 by American Society of Hematology
2012 by American Society of Hematology Common Types of HIV-Associated Lymphomas DLBCL includes primary CNS lymphoma (PCNSL) Burkitt Lymphoma HIV-positive patients have a 60-200 fold increased incidence
More informationALL Phase 2 Induction (25-60 years)
ALL Phase 2 (25-60 years) INDICATION of remission in Adult Acute Lymphoblastic Leukaemia (ALL) patients This protocol is suitable for patients aged 25-60 years. It may sometimes be used in older patients
More informationAggressive NHL and Hodgkin Lymphoma. Dr. Carolyn Faught November 10, 2017
Aggressive NHL and Hodgkin Lymphoma Dr. Carolyn Faught November 10, 2017 What does aggressive mean? Shorter duration of symptoms Generally need treatment at time of diagnosis Immediate, few days, few weeks
More informationBrad S Kahl, MD. Tracks 1-21
I N T E R V I E W Brad S Kahl, MD Dr Kahl is Associate Professor and Director of the Lymphoma Service at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical
More informationR-GDP: Rituximab, Gemcitabine, Dexamethasone &Cisplatin
: Rituximab, Gemcitabine, Dexamethasone &Cisplatin INDICATION Relapsed or refractory Hodgkin and non-hodgkin lymphoma. Omit Rituximab for patients with Hodgkin Lymphoma or high grade T cell non-hodgkin
More informationStem cell transplantation. Dr Mohammed Karodia NHLS & UP
Stem cell transplantation Dr Mohammed Karodia NHLS & UP The use of haemopoeitic stem cells from a donor harvested from peripheral blood or bone marrow, to repopulate recipient bone marrow. Allogeneic From
More informationNCCP Chemotherapy Regimen
INDICATIONS FOR USE: Azacitidine i INDICATION ICD10 Regimen Code *Reimbursement Status Intermediate-1 and low risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System
More informationPathology of Hematopoietic and Lymphoid tissue
Pathology of Hematopoietic and Lymphoid tissue Peerayut Sitthichaiyakul, M.D. Department of Pathology and Forensic Medicine Faculty of Medicine, Naresuan University CONTENTS White blood cells and lymph
More informationHaematological Emergencies (Part 1) Ray Mun Koo Haematology Advanced Trainee Canberra Hospital
Haematological Emergencies (Part 1) Ray Mun Koo Haematology Advanced Trainee Canberra Hospital Case Number 1 43 year old male presenting with fevers, abdominal distension and weight gain over 2 weeks.
More informationRecommended Timing for Transplant Consultation
REFERRAL GUIDELINES Recommended Timing for Transplant Consultation Published jointly by the National Marrow Donor Program /Be The Match and the American Society for Blood and Marrow Transplantation BeTheMatchClinical.org
More informationBC Cancer Protocol Summary for Therapy of Acute Myeloid Leukemia Using azacitidine and SORAfenib
BC Cancer Protocol Summary for Therapy of Acute Myeloid Leukemia Using azacitidine and SORAfenib Protocol Code Tumour Group Contact Physician ULKAMLAS Leukemia/BMT Dr. Donna Hogge ELIGIBILITY: Acute myeloid
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Anemia(s), 412 426 categories in morphologic approach to, macrocytic, 412 414 microcytic, 412 414 normocytic, 412 413 categorizing, 412
More informationLymphocyte Predominant Hodgkin s Lymphoma. Case Presentation. How would you treat the patient?
Lymphocyte Predominant Hodgkin s Lymphoma Wei Ai, MD, PhD Assistant Clinical Professor University of California, San Francisco January 2010 Case Presentation 32 yo male, diagnosed with stage IIIA lymphocyte
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationAcute myeloid leukemia. M. Kaźmierczak 2016
Acute myeloid leukemia M. Kaźmierczak 2016 Acute myeloid leukemia Malignant clonal disorder of immature hematopoietic cells characterized by clonal proliferation of abnormal blast cells and impaired production
More informationHodgkin s Lymphoma (Hodgkin s Disease, HD) PI HD-1 Protocol
1 Hodgkin s Lymphoma (Hodgkin s Disease, HD) PI HD-1 Protocol NCCN Pacific Island Working Group Clinical Members Scott Macfarlane Peter Bradbeer Jane Skeen Rob Corbett Radhika Sandilya PI HD-1 Updated
More informationMS.4/ Acute Leukemia: AML. Abdallah Al Abbadi.MD.FRCP.FRCPath Feras Fararjeh MD
MS.4/ 27.02.2019 Acute Leukemia: AML Abdallah Al Abbadi.MD.FRCP.FRCPath Feras Fararjeh MD Case 9: Acute Leukemia 29 yr old lady complains of fever and painful gums for 1 week. She developed easy bruising
More informationMANAGEMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA. BY Dr SUBHASHINI 1 st yr PG DEPARTMENT OF PEDIATRICS
MANAGEMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA BY Dr SUBHASHINI 1 st yr PG DEPARTMENT OF PEDIATRICS Introduction The management of ALL, the most common childhood malignancy (1/3 rd of all malignancy), has
More informationAcute Lymphoblastic Leukaemia
Acute Lymphoblastic Leukaemia Terri Boyer 17 th October 2006 Overview Disease information: Aetiology of ALL proposed theory, contributing factors Symptoms Complications Diagnostic approaches - morphology
More informationTRANSPARENCY COMMITTE OPINION. 19 December 2007
The legally binding text is the original French version TRANSPARENCY COMMITTE OPINION 19 December 2007 ATRIANCE 5 mg/ml, Solution for Infusion Pack of 6 vials (571 348-9) Applicant: GlaxoSmithKline nelarabine
More informationElements for a Public Summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Acute myeloid leukemia (AML) Acute myeloid leukemia (AML) is a type of cancer characterized by the rapid growth of abnormal white
More informationLymphoma/CLL 101: Know your Subtype. Dr. David Macdonald Hematologist, The Ottawa Hospital
Lymphoma/CLL 101: Know your Subtype Dr. David Macdonald Hematologist, The Ottawa Hospital Function of the Lymph System Lymph Node Lymphocytes B-cells develop in the bone marrow and influence the immune
More informationR-IDARAM. Dexamethasone is administered as an IV infusion in 100mL sodium chloride 0.9% over 30 minutes.
R-IDARAM Indication Secondary CNS lymphoma ICD-10 codes Codes with a prefix C85 Regimen details Day Drug Dose Route 1 Rituximab 375mg/m 2 IV infusion 1 Methotrexate 12.5mg Intrathecal 1 Cytarabine 70mg
More informationEarly diagnosis saves lives #SpotLeukaemia
Early diagnosis saves lives #SpotLeukaemia Leukaemia... is a blood cancer affects people of all ages Leukaemia symptoms are hard to spot, as they are similar to the symptoms of common, unrelated conditions.
More informationBlood Cancer: Chronic Myelogenous Leukaemia
Published on: 30 May 2017 Blood Cancer: Chronic Myelogenous Leukaemia What Is Cancer? The body is made up of cells that grow and die in a controlled way. Sometimes, cells keep dividing and growing without
More informationPregnancy in the middle of adjuvant treatment of Her2 positive breast cancer
ESMO Preceptorship Programme ESMO Preceptorship ADOLESCENTS & YOUNG ADULTS MALIGNANCIES Lugano, Switzerland 11-12 May 2018 Petra Vuković, University Hospital for Tumors, University Hospital Center Sestre
More informationRelapsed/Refractory Hodgkin Lymphoma
Relapsed/Refractory Hodgkin Lymphoma Anas Younes, MD Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center New York, New York, United States Case Study 32-year-old woman was diagnosed with stage
More informationPUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) METHOTREXATE ORION 2.5 MG & 10 MG TABLET (METHOTREXATE DISODIUM) DATE: , VERSION 1.
PUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) METHOTREXATE ORION 2.5 MG & 10 MG TABLET (METHOTREXATE DISODIUM) DATE: 23-6-2016, VERSION 1.2 VI.2 Elements for a Public Summary Methotrexate is indicated for:
More informationAll Wales Lymphoma Panel Lymphoma Course April 2015 Wales Millennium Centre Cardiff
All Wales Lymphoma Panel Lymphoma Course 23-24 April 2015 Wales Millennium Centre Cardiff Case Histories Online slides at: http://dental.uwcm.ac.uk:82/awlp%20course%202015/view.apml? Professor Sebastian
More informationCLL & SLL: Current Management & Treatment. Dr. Isabelle Bence-Bruckler
CLL & SLL: Current Management & Treatment Dr. Isabelle Bence-Bruckler Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of white blood cell B lymphocyte Lymphocytic Cancer
More informationPregnancy and Neurological Disorders
Pregnancy and Neurological Disorders Myles Connor NHS Borders and University of Edinburgh, United Kingdom Outline Why is it important? Specific conditions Eclampsia Cerebrovascular disease Epilepsy Idiopathic
More information